Uniek schreef op 22 september 2020 12:52:
Onderzoek Biocryst naar "doorbraak' aanvallen
Hereditary Angioedema Patients Report Breakthrough Attacks on Current Injectable/Infused
Prophylaxis Medication
June 6, 2020
—Data presented at European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress—
RESEARCH TRIANGLE PARK, N.C., June 06, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented
findings from two patient surveys conducted to gain insights into patients’ current hereditary angioedema (HAE) treatment expectations, experience
and satisfaction. Patient-reported attack history shows patients treated with current injectable or infused prophylactic medications (Takhzyro®,
Haegarda®, Cinryze®) continue to experience breakthrough attacks with a mean ranging from 0.9 to 1.8 attacks over the three months prior to survey.
In addition, the majority of patients surveyed did not expect to have zero attacks even when taking prophylaxis therapy.
The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress.
“While the injectable and infused medications introduced over the past 12 years have provided added prophylactic attack control for HAE patients,
most patients in the study continue to experience breakthrough attacks, and medication adherence continues to be a challenge. HAE patients have
indicated an interest in new preventative treatment options, with the majority agreeing that they would prefer an oral medication, despite liking their
current prophylactic medication,” said Jinky Rosselli, vice president of global business analysis and operations at BioCryst, who conducted the
research.
. deze doorbraakaanvallen worden nog steeds voor een groot deel met Ruconest behandeld en ik moet nog zien of Biocryst dit van pharming kan afsnoepen want aan deze Pil zal wellicht een mooi prijskaartje hangen zoals Takhzyro.
btw ik zie steeds meer providers ruconest voorschrijven, van Takhzyro vind je vrij weinig te $$$$$$